Patient Data is the LIfeblood of Innovation, So why is it Locked Away
Traditional security models weren’t designed for a world where sensitive patient data lives across Contract Research Organisations (CROs), SaaS platforms, cloud storage, and real-world evidence networks.
As a CDO, you’re expected to unlock value from data you’re barely allowed to touch. And that’s before federated trials, or global collaboration come into play. We’ve spoken to data leaders across Europe’s leading pharmaceutical organisations. The challenge isn’t strategy—it’s access, visibility, and control
As a CDO, you’re expected to unlock value from data you’re barely allowed to touch. And that’s before federated trials, or global collaboration come into play. We’ve spoken to data leaders across Europe’s leading pharmaceutical organisations. The challenge isn’t strategy—it’s access, visibility, and control
We’ve spoken to data leaders across Europe’s leading pharmaceutical organisations. The challenge isn’t strategy—it’s access, visibility, and control
You Own the Data. So Why Don’t You Own Its Protection?
Data is at the heart of every innovation, trial, and safety mandate. And
you’re the one expected to unlock its value—fast, safely, and globally.
But Common Blockers keep showing Up:
- Trial and real-world evidence (RWE) data move faster than your policies
- AI and analytics are blocked by fragmented security
- Privacy constraints stall collaboration with partners
- Regulators add friction to every workflow
- Compliance tools weren’t built for patient-level sensitivity
How Protegrity Helps Take Control
- Protects sensitive fields (PII, PHI, trial data) without disrupting usage
- Applies consistent policies across SaaS, CROs, clouds and legacy
platforms - Enables AI/ML on protected data without exposing identifiers
- Automates compliance and auditability at every access point
- Cuts time-to-data from months to days, safely and at scale